Cyprotex : Launch of New Enhanced Version of chemPK™ Workflow Solution for Predicting Human Pharmacokinetics Directly from Chemical Structure

Cyprotex PLC
('Cyprotex' or 'the Company')
Launch of New Enhanced Version of chemPK™ Workflow Solution
for Predicting Human Pharmacokinetics Directly from Chemical Structure

Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of version 2 of its in silico modelling solution, chemPK™, which predicts human pharmacokinetics directly from chemical structure. Pharmacokinetics is defined as the study of the concentration of a drug or chemical in the body over time, and is related to its absorption, distribution, metabolism and excretion. Understanding the pharmacokinetics is important for understanding the efficacy (effectiveness) or potential toxicity of drugs or chemicals following their administration.

The original version of chemPK™ was able to predict human pharmacokinetics following administration of a single oral dose. Version 2 now has the ability to predict human pharmacokinetics following administration of both oral and intravenous dose. It is also able to simulate repeat-dose administration and so is more relevant to the typical dosing regimen within the clinic. Unlike most competing products, chemPK™ uses a PBPK (physiologically-based pharmacokinetic) modelling approach which is a more robust technique for this purpose. The software is easy to implement and use. It operates on the freely available KNIME Analytics Platform for workflow management which facilitates integration with a wide range of other cheminformatics, analytics and modelling tools.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'chemPK™ is a valuable virtual screening tool which can be used at an early stage prior to chemical synthesis of a molecule. The recently developed version 2 improves the relevance of chemPK™ to different dosing routes and regimens in the clinic. Cyprotex have built an impressive range of software products for predicting pharmacokinetic processes and toxicity which are now being utilised within the industry for directing chemistry and prioritising in vitro and in vivo screening.'

For Further Information

Cyprotex PLC
Tel: [phone]
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
[e-mail]
www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex)
Tel: [phone]
Shaun Dobson
[e-mail]
Jen Boorer
[e-mail]
www.nplus1singer.com

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1400 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com.